This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
PTC Therapeutic’s Upstaza gene therapy for patients with genetic disorder AADC deficiency has been recommended for approval in the EU, setting up another test of the commercial prospects for gene therapies in the bloc. Once full approval is granted Upstaza (eladocagene exuparvovec) will become the first disease-modifying treatment for AADC (aromatic L-amino acid decarboxylase) deficiency, as well as the first gene therapy directly administered into the brain, said PTC.
A study that will look at the feasibility of tracking people’s lifestyle habits for an extended period using a wearable device has got underway in Japan, backed by drugmakers Takeda and Daiichi Sankyo. The device will be worn by 2,000 people for a year, harvesting data on sleep status, heart rate, and activity levels, according to the study partners, which also include digital health and telemedicine firm MICIN and Tohoku University.
Tune in to this episode of the Pharma Marketing Podcast with Bharti Rai, Novartis VP, Chief Commercial Operations, Insight, Analytics Officer Data & Digital, for a deeper dive into what’s ahead for 1st and 3rd party data, insights, analytics & digital data. The post Bharti Rai, Novartis VP & Head of Commercial Acceleration on What’s Ahead for 1st and 3rd party data, Insights, Analytics & Digital Data appeared first on Pharma Marketing Network.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Telehealth company Amwell has marked Mental Health Awareness month with the launch of a digital tool that will deliver cognitive behavioural health interventions across a spectrum of mental illness. The suite – which combines virtual therapy and psychiatry, optional coaching, and digital mental health programmes tailored to the patient’s needs – has been developed in the wake of Amwell’s acquisition last year of SilverCloud Health.
With Veeva Link for Key People, LEO Pharma is looking to deepen its efforts to engage with knowledgeable medical professionals in the dermatology community.
AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to control symptoms throughout a 24-hour period. ABBV-951 is based on foslevodopa and foscarbidopa – prodrugs of two widely-used oral Parkinson’s drugs – and is delivered via a subcutaneous pump once a day.
52
52
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to control symptoms throughout a 24-hour period. ABBV-951 is based on foslevodopa and foscarbidopa – prodrugs of two widely-used oral Parkinson’s drugs – and is delivered via a subcutaneous pump once a day.
Sanofi and Regeneron have added another string to the bow of their immunology blockbuster Dupixent with an FDA approval in eosinophilic oesophagitis (EoE), which could help the drug reach its €10 billion peak sales target. Dupixent (dupilumab) made more than €5 billion last year from its current uses in atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps, and EoE is one of a clutch of additional indications that Sanofi and Regeneron are relying on to push sales ev
This article follows part one of our two-part series, in which we discussed how USAID invests in digital infrastructure as part of its development and humanitarian assistance programmes. . Adele Waugaman, senior digital health coordinator of the COVID-19 response at the United States Agency for International Development (USAID), discusses the value of establishing donor partnerships and how those collaborations can improve digital health options globally. .
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Sanofi’s Genzyme unit has moved a step closer to securing EU approval for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after scoring a positive opinion from the CHMP. Xenpozyme (olipudase alfa) is set to become the first and only approved therapy for ASMD type A/B or ASMD type B, two forms of a group of genetic disorders also known as Niemann-Pick disease in which fats build up within cells, causing them to die and disrupting tissue
52
52
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content